AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00212095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and ketoconazole
Description: Docetaxel will be obtained locally from the manufacturer. Storage conditions for unopened vials, reconstitution, and storage conditions for the reconstituted solution will follow the manufacturer's recommendations. Docetaxel solutions should be prepared and stored in glass, polypropylene or polyolefin containers. Non-PVC containing and polyethylene-lined administration sets should be used.~Ketoconazole is available commercially in 200 mg tablet. Ketoconazole is to be administered at a dose of 200mg BID orally for six doses, starting two days before docetaxel administration. The fifth dose should be administered on the day of and before administering docetaxel, while the sixth dose should be administered in the evening of the day of docetaxel administration.
Study NCT01026961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine HCL
Description: Phenylephrine HCL 10mg
Study NCT01026961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCL/Acetaminophen/Dimethindene Maleate
Description: Phenylephrine HCL 10mg/Acetaminophen 500mg/Dimethindene Maleate 1mg
Study NCT03845920 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: tdcs (sham/anodal) + drug (placebo/tyrosine)
Description: tDCS= A DC Stimulator Plus (neuroConn, Germany) with one 5 cm x 7 cm rubber electrode (anode) and a 10 cm x 10 cm (cathode; reference electrode), encased in saline soaked sponges will be used. The anode will be positioned over the left dlPFC, centered on F3 in the 10e20 electroencephalography (EEG) system, while the cathode on the contralateral supraorbital ridge (Fp2).Current will be delivered at 1.5mA for 20 min plus 30 s fade in/fade out periods.For sham stimulation, the current will be faded in over 30 s, at 1.5mA and then will be switched off.~Drugs= 2.0 g of L-Tyrosine and 2.0 g of the placebo microcrystalline cellulose will be dissolved in 400ml of orange juice as per previously published protocols.
Study NCT03845920 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: tdcs (sham/anodal) + drug (placebo/tyrosine)
Description: tDCS= A DC Stimulator Plus (neuroConn, Germany) with one 5 cm x 7 cm rubber electrode (anode) and a 10 cm x 10 cm (cathode; reference electrode), encased in saline soaked sponges will be used. The anode will be positioned over the left dlPFC, centered on F3 in the 10e20 electroencephalography (EEG) system, while the cathode on the contralateral supraorbital ridge (Fp2).Current will be delivered at 1.5mA for 20 min plus 30 s fade in/fade out periods.For sham stimulation, the current will be faded in over 30 s, at 1.5mA and then will be switched off.~Drugs= 2.0 g of L-Tyrosine and 2.0 g of the placebo microcrystalline cellulose will be dissolved in 400ml of orange juice as per previously published protocols.
Study NCT04943809 — intervention group
Intervention type: DEVICE
Intervention: POD 26P AY FT
Description: Routine cataract surgery
Study NCT01857830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Retreat
Description: The intervention is a one week meditation and yoga retreat hosted at the La Costa Resort and Spa in Carlsbad, CA.
Study NCT01734915 — intervention group
Intervention type: DEVICE
Intervention: Circulating tumor cell chip
Description: three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip
Study NCT03499457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: chalange test of 50 mg, and after an hour 500 mg
Study NCT03451916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: PLX-PAD (120 subjects): 150×10\^6 PLX-PAD cells (10×10\^6 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte
Study NCT03451916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO \[v/v\], 5% HSA \[w/v\], and PlasmaLyte, without cells).
Study NCT00550134 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires, MRI, Comet assay and Cell senescence
Description: Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
Study NCT01857830 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator Relaxation Group
Description: Participants are randomized to stay at La Costa Resort and Spa for 6 days. Participants will receive daily meals similar to the meals for those in the retreat group. Participants will also receive a daily one hour lecture on topics related to longevity and health.
Study NCT06374537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Therapy
Description: Participants will attend 2 muscle therapy sessions a week for 12 months, for one hour each.
Study NCT05047562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates Group
Description: 16 Pilates exercise sessions twice a week for 2 months.
Study NCT05047562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Segmental Stabilization group
Description: 16 sessions of segmental stabilization exercises, 2 times a week for 2 months.
Study NCT00566943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSD Veritas Collagen Matrix
Description: Roux-en-Y gastric by-pass surgery. Surgeon creates a small pouch from the stomach and then by-passes a large portion of the small intestine. The body cannot absorb as many calories or nutrients thus resulting in weight loss.
Study NCT00566943 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric by-pass surgery with no buttress
Description: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple line including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine intestine to mesentery.
Study NCT01925261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 50mg
Study NCT01925261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 100mg
Study NCT01925261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 200mg
Study NCT01925261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 20mg
Study NCT01925261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00550134 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires, MRI, Comet assay and Cell senescence
Description: Neuropsychological and psychological testing, MRI, Comet assay and Cell senescence
Study NCT01778738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy
Description: Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention
Study NCT01778738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrecomy
Description: Vertical sleeve gastrectomy
Study NCT01778738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bastric bypass
Description: Gastric bypass surgery
Study NCT02010658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Aid
Study NCT04865549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNB + TAD + Lymphadenectomy
Description: Sentinel Node Biopsy + Targetted Axillary Dissection (Previously to surgery marked cN1 node) + Lymphadenectomy
Study NCT00138073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Web-based waveform interpretation guide
Description: Use of an educational website.
Study NCT01192529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supressi. T-Diet plus Range
Description: Supressi is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patients with neurodegenerative diseases and related malnutrition.~Experimental group patients will receive, 2 packs per day (Tetra brik aseptic)of 200 ml for 6 months.
Study NCT01192529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Protein. T-Diet plus Range
Description: T-Diet plus High Protein is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patient with related malnutrition and with increased protein requirements.
Study NCT02090621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis
Description: Extracorporeal photopheresis with Methoxsalen(UVADEX)and immunosuppression reduction Extracorporeal photopheresis (ECP) is an immunomodulatory excellent technical tolerated initially designed for the treatment of cutaneous T-cell lymphoma and various autoimmune diseases, which has been proven effective in reversing episodes acute heart transplants, kidney and lung rejection, and in the treatment of Disease graft versus host both acute and chronic.
Study NCT03320850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA and Hydrogel admixture
Description: BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation
Study NCT03320850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Hydrogel admixture
Description: Placebo and Hydrogel admixture administered as a single intravesical instillation
Study NCT02580669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: A neuropsychological assessment is done
Study NCT02580669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurologic consultation
Description: A neurologic consultation is done
Study NCT02580669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRIs (with vasoreactivity testing)
Description: MRIs (with vasoreactivity testing) is done
Study NCT02464761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visudyne
Study NCT01664949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose Based Eye Drop Formulation A
Description: Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
Study NCT01664949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops
Description: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
Study NCT03195647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium
Description: The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol.
Study NCT03195647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium
Description: The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol.
Study NCT02170896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule A
Study NCT02170896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule B
Study NCT02170896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule C
Study NCT02170896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS Capsule D
Study NCT02170896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 1048 MS tartaric acid solution
Study NCT02170896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Study NCT02170896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Study NCT04178642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment
Description: Patients will receive the standard treatment protocol consisting of a percutaneous destruction of the tumor. In addition they will receive an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin (Zavedos®, Pfizer), which is an anthracycline antineoplastic agent, mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet), which is a contrast agent.
Study NCT04178642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous destruction of the tumor
Description: Patients will received the standard treatment protocol consisting of a percutaneous destruction of the tumor.
Study NCT03250481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Sedation targeted to RASS -3-0 or RI 20-40
Study NCT03250481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Sedation targeted to RASS -3-0 or RI 20-40
Study NCT03948035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: i.v. infusion. Induction 6 cycles: 10mg/kg BW D1,8,15,22 of cycle 1 and 2, D1,15 of cycles 3-6. Consolidation 4 cycles: 10mg/kg BW D1,15 of cycle 1-4. Maintenance 28-day cycles: 20mg/kg BW D1 of each 28-day cycle.
Study NCT03948035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.
Study NCT03948035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.
Study NCT03948035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.
Study NCT03948035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.
Study NCT03948035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .
Study NCT03948035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .
Study NCT03948035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplant
Description: autologous stem cell transplant
Study NCT03948035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autologous stem cell transplant
Description: autologous stem cell transplant
Study NCT02901275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
Study NCT02901275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
Study NCT02901275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
Study NCT03148457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)
Description: Early treatment will be started within 48 hours after symptom onset (minor and moderate ischaemic stroke) or at day 6 + 1 day after symptom onset (major ischaemic stroke)
Study NCT03148457 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)
Description: Patients in the control arm will receive late treatment as per current recommendations (i.e. minor ischaemic stroke after day 3 + 1 day, moderate ischaemic stroke after day 6 + 1 day and major ischaemic stroke after day 12 + 2 day).
Study NCT01652326 — intervention group
Intervention type: DRUG
Intervention: Diazepam
Study NCT03122613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: 3g of Curcumin per day
Study NCT03122613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g of Curcumin Placebo per day
Study NCT03373058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: HIPEC is performed as postoperative chemotherapy after cytoreductive surgery for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 48h after cytoreductive surgery: Paclitaxel 175 mg/m\^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The HIPEC regimens are Docetaxel 75 mg/m\^2 and cisplatin 75 mg/m\^2, respectively, 43°C, 90min.
Study NCT03373058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cytoreductive surgery
Description: Cytoreductive surgery (CRS) is performed when Faggoti value is less than 6 via laparoscopic exploration.
Study NCT03373058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cytoreductive surgery
Description: Cytoreductive surgery (CRS) is performed when Faggoti value is less than 6 via laparoscopic exploration.
Study NCT03373058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group.
Study NCT03373058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group.
Study NCT03181503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD14152 Dose A
Description: 3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
Study NCT03181503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD14152 placebo
Description: 3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
Study NCT04056273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guide sheath group
Description: After the lesion was found by rEBUS, insert the rEBUS into a guide sheath and re-locate the lesion. Fix the guide sheath at that position and perform transbronchial biopsy and brushing through the guide sheath.
Study NCT04056273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group
Description: After the lesion was found by rEBUS, mark the location and depth. Insert the biopsy forceps and cytology brush to the marked depth of that bronchiole to perform biopsy and brushing.